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Abstract
The drug-induced QT prolongation predisposes to development of torsades de pointes (TdP)
ventricular tachycardia and sudden death. The association between specific drug and develop-
ment of TdP is difficult to document, therefore, QT prolongation is considered as a surrogate
marker of the proarrhythmia risk. Most of the drugs prolong QT interval usually by blocking
the potassium IKr current or altering trafficking of proteins forming the channel. Improved
understanding of ion channel structure and kinetics and its role in repolarization has tremen-
dous impact on understanding of the mechanisms of drug-induced QT prolongation and TdP.
Proarrhythmia caused by a QT-prolonging drug occurs infrequently, and usually multiple
factors need to operate to precipitate such an event including a combination of two or more
drugs affecting the same pathway, hypokalemia, and possibly genetic predisposition. ECG
provides unique opportunity to ensure safety of administered therapy. QT measurement is the
most routine approach to a drug safety monitoring, however, there are many challenges related
to methodology of measurements, accuracy of measurements, or optimal heart rate correction.
Since drugs affecting repolarization not only prolong QT but also they alter T wave morpholo-
gy, novel computerized methods quantifying these changes are being developed to assist physi-
cians and drug manufacturers in monitoring safety of the drugs. The response of a patient to
a drug is very individual and therefore an individualized system of drug administration and
monitoring needs to be developed, which takes into account baseline QTc duration and its
changes after a drug was introduced. (Cardiol J 2007; 14: 523–533)
Key words: drug-induced QT prolongation, QT interval, torsade de pointes, long
QT syndrome
Introduction
A prolonged QT interval predisposes to the
development of ventricular tachyarrhythmias such
as torsades de pointes (TdP) and ventricular fibril-
lation, which could cause syncope, cardiac arrest,
or sudden cardiac death [1–4]. Drug-induced QT
prolongation and TdP has been recognized as a side
effect of many commonly used medications. The
association between specific drug and development
of TdP is difficult to document, therefore, QT pro-
longation is considered as a surrogate marker of the
proarrhythmia risk. Some examples of QT-prolong-
ing drugs are listed in Table 1 whereas an up-to-
date information can be found at the website
www.qtdrugs.org supported by The Critical Path
Institute and University of Arizona [5]. More sin-
gle and combination drugs are being used as docu-
mented by 2.8 billion prescriptions filled in the US
in the year 2000, averaging 10 prescription per eve-
ry person in the United States [6]. The increasing
incidence of polypharmacy in current clinical prac-
tice causes a need for further attention to side
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effects of drugs and their interactions, possibly lead-
ing to adverse fatal events. Adverse drug reactions
are responsible for significant morbidity and mor-
tality, possibly accounting for up to an estimated
100,000 deaths annually [7, 8].
Cases of life-threatening ventricular tachyar-
rhythmias and sudden death, associated with pre-
scription drugs, have been reported since the 1960’s,
however this association was broadly recognized in
the 1980’s [9–13]. The first major series of quinidine-
induced sudden deaths and subsequently the results
of the CAST and SWORD trials brought further at-
tention to the proarrhythmic effects of antiarrhyth-
mic drugs [14]. In the early 1990’s, the adverse ef-
fects of terfenadine (an antihistamine drug) brought
much attention to the possibility of non-cardiac drugs
being associated with torsade de pointes and sudden
cardiac death [15]. The medical community and reg-
ulatory agencies (Food and Drug Administration;
FDA in the USA) became more sensitive to the pos-
sibility that drugs causing QT prolongation might
increase the risk of sudden death. Ultimately, ter-
fenadine was withdrawn from the US market in 1998
after a reported 350 deaths attributed to the drug.
Table 2 shows other drugs on which subsequent reg-
ulatory action was taken. This increasing awareness
of drug-induced QT prolongation in the 1990’s was
also stemming from tremendous progress in research
focused on the genetic background and mechanisms
underlying congenital long QT syndrome (LQTS).
The magnitude of the problem related to drug-
induced QT prolongation and sudden death might
still be underappreciated. A recent study by De
Bruin et al. [16] evaluated the associations between
cardiac arrest and the number and dose of non-car-
diac drugs known to have QT prolonging effect.
Patients taking such drugs had a 2-fold increase in
the risk of sudden death and this risk further in-
creased with higher doses of the drug and with in-
creased number of drugs. This study emphasizes
the clinical importance of drug-induced arrhythmi-
as especially in the setting of underlying cardiovas-
cular disorders as well as the possible interaction
of several drugs frequently taken without knowl-
edge of their mutual impact.
Lessons from congenital forms of
long QT syndrome
The QT interval on an ECG is a reflection of
electrical activity of the myocardium driven by the
multiplicity of ion currents flowing across myocar-
dial cell membranes through ion channels. During
the last decade mutations in different genes encod-
ing sodium and potassium ion channels have been
found to cause the congenital LQTS, a familial
Table 1. Drugs that prolong the QT interval (for more complete listing please visit www.qtdrugs.org).
Category Drugs
Antihistamines Astemizole, terfenadine
Anti-infectives Amantadine, clarithromycin, chloroquine, erythromycin, grepafloxacin,
moxifloxacin, pentamidine, sparfloxacin, trimethoprim-sulfamethoxazole
Antineoplastics Tamoxifen
Antiarrhythmics Quinidine, sotalol, procainamide, amiodarone, bretylium, disopyramide, flecainide,
ibutilide, moricizine, tocainide, dofetilide
Antilipemic agents Probucol
Calcium channel blockers Bepridil
Diuretics Indapamide
Gastrointestinal agents Cisapride
Hormones Fludrocortisone, vasopressin
Antidepressants Amiryptyline, amoxapine, clomipramine, imipramine, nortriptyline, protriptyline
Antipsychotic Chlorpromazine, haloperidol, perphenazine, quetiapine,  risperidone, sertindole,
thioridazine, ziprasidone, doxepin
Table 2. Medications withdrawn due to torsades
de pointes.
Drug Class Date
withdrawn
Terfenadine Antihistamine 1998
Sertindole Antipsychotic 1998
Astemizole Antihistamine 1999
Grepafloxacin Antibiotic 1999
Cisapride GI Prokinetic 2000
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disorder characterized by QT prolongation and a pro-
pensity to ventricular tachyarrhythmias (usually
torsades de pointes) frequently leading to sudden
death at a young age. Identification of specific ion
channel abnormalities causing QT prolongation in
LQTS has increased our understanding of mecha-
nisms related to myocardial electrophysiology and
cardiac arrhythmias [4, 17, 18]. QT prolongation in
LQTS could be caused by a decrease outflow of po-
tassium ions (LQT1 — mutations of KCNQ1 gene,
LQT5 — mutations of minK gene, both encoding
the potassium channel for the IKs current; LQT2 —
mutations of HERG gene, LQT6 — mutations of
MiRP1, both encoding the potassium channel for IKr
current) or by an increased inflow of sodium ions
(LQT3 — mutations of the SCN5A sodium channel
gene). Other forms of LQTS are very rare and they
represent few disorders accompanied by QT prolon-
gation, but importantly they confirm the mechanis-
tic involvement of the ion channels and related pro-
teins. The function of the rapidly activating delayed
rectifier potassium current (Ikr), coded by the HERG
gene, is most frequently affected by drugs inducing
QT prolongation. However, not all medications that
block Ikr are associated with TdP, which means that
IKr blockade and QT prolongation might not be suf-
ficient to trigger TdP. QT prolongation must be
accompanied by a significant increase in transmu-
ral dispersion of repolarization to create conditions
suitable for the development of TdP. Calcium chan-
nel blockade by drugs may also cause QT prolon-
gation and lead to TdP, therefore compounds af-
fecting those pathways must be considered as po-
tentially proarrhythmic. There is also evidence for
involvement of other ion channels (including car-
diac sodium and chloride channels) in drug-induced
cases of TdP. However, the majority of drugs rare-
ly act on just one specific channel and the concom-
itant effect on different channels might ultimately
govern lower or higher likelihood of drug-induced
QT prolongation and TdP.
There are significant differences in repolari-
zation in the various layers of the myocardium,
with the epicardial cells having the shortest ac-
tion potential duration, endocardial cells having
an intermediate duration, and M cells having the
longest action potential duration [19, 20]. QT du-
ration on ECG represents the longest repolariza-
tion in the M cell zone. This physiologic trans-
mural dispersion of repolarization usually does
not lead to TdP.  However, proarrhythmic states
may arise as a result of specific gene mutations
or actions of medications causing selective action
potential prolongation in certain areas of the heart
(usually M cells) that lead to increased transmu-
ral repolarization gradients (Fig. 1) [20]. This in-
creased transmural gradient may contribute to
reentrant arrhythmias leading to TdP. It is worth
stressing that not all drugs prolonging repolari-
zation cause TdP. For example, amiodarone is
known to prolong QT duration, but since this drug
is not increasing transmural heterogeneity of
Figure 1. Transmembrane action potentials and transmural electrocardiograms in control and LQT1, LQT2, and LQT3
models of LQTS (arterially perfused canine left ventricular wedge preparations), and clinical ECG (lead V5) of patients
with LQT1 (KvLQT1 defect), LQT2 (HERG defect), and LQT3 (SCN5A defect) syndromes. Isoproterenol plus chroma-
nol 293B, an IKs blocker, d-sotalol plus low K+, and ATX-II, an agent that slows inactivation of late INa, are used to
mimic the LQT1, LQT2, and LQT3 syndromes, respectively; ECG — electrocardiogram; Endo — endocardial region;
Epi — epicardial region; M — midmyocardial (from reference 20 with permission).
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repolarization (or it might decrease it), TdP is not
observed in patients taking this drug. Similarly,
novel compound ranolazine may increase QT du-
ration but simultaneously decreases heterogene-
ity of repolarization. Interestingly both of these
drugs are mild calcium and sodium channel block-
ers, which might contribute to a decreased pro-
pensity to proarrhythmias [21].
Recent progress in understanding of ion chan-
nel structure and function has provided evidence
for the mechanisms associated with HERG chan-
nel and IKr current abnormalities. Numerous med-
ications cause QT prolongation by blocking Ikr due
to their binding affinity to sites within the HERG
channel cavity, some other may cause abnormal
trafficking of proteins forming the channel from
inside the cell towards the cellular membrane.
Abnormal trafficking of channel proteins may re-
sult in a decreased number of channels in cellular
membrane or expression of dysfunctional channels
[22, 23]. Some of the proteins do not reach the
membrane at all, and some reach them as imper-
fect, defective proteins that are not fully function-
al, therefore unable to pass the expected number
of potassium ions through the pore of the channel.
LQT2 patients as well as patients who never had
a LQTS diagnosed but might have genetic polymor-
phism of HERG protein are particularly prone to
developing QT prolongation due to drugs blocking
this channel. Other individuals with normal func-
tion and structure of the channel who develop
drug-induced QT prolongation might have affinity
to experience an entrapment of the drug molecule
within the pore of the channel causing decreased
outward potassium current.
QT Interval as a measure of
ventricular repolarization
The QT interval is considered a practical
measure of repolarization duration that could be
obtained from routine ECG recordings. Despite
this presumed simplicity, QT measurement re-
mains a challenge both for clinicians and for spe-
cialized academic or commercial ECG core labs.
Challenges relate to number of factors, but the
most frequent difficulties consist of delineating the
end of T wave when the T wave is flat, bifid, bi-
phasic or overlapping on a U wave (Fig. 2) [24].
Identifying the end of the T wave and measurement
of QT may lead to quite significant differences
based on experience of the reader, as it was shown
by Viskin et al. [25] who demonstrated that only
about 40% of internists and 70% of cardiologists
were able to measure it properly in comparison to
measurements done by a group of experts.
Clinicians rely on the QT interval measured
usually in one lead (frequently limb lead II) of the
standard 12-lead ECG, however, the time measured
from the earliest Q wave onset in any lead to the
latest offset of T wave in any lead is the most relia-
ble reflection of repolarization duration in the myo-
cardium. On any single standard 12-lead ECG, there
may be differences in the QT interval in separate
leads, referred to as QT dispersion [26]. QT disper-
sion is rarely used in the clinical arena due to its
time-consuming nature, conceptual and methodo-
logical limitations, and poor reproducibility during
manual measurements [26]. QT dispersion meas-
urements should not be used as a standard tool in
clinical practice or drug studies.
Evaluating the QT interval on serial ECGs (e.g.,
off and on drug) requires using the same leads to
be compared between different ECG tracings. Since
QT duration changes with heart rate, usually the
Figure 2. Examples of complex repolarization patterns
with identification of QT intervals (from reference 24
with premission).
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Normal values of the QT interval are sex- and
age-dependent with women and children having
longer QTc duration than men (Table 3) [34]. These
values are presented for Bazett’s formula, which is
the most popular heart rate correction used in clini-
cal practice. It is worth stressing that normal values
will be somewhat different when using other heart
rate correction formulae. A different density of po-
tassium ion channels in male vs. female myocardium,
differential effects of estrogens and androgens on the
QT interval, as well as heart rate seem to underlie
this sex- and age-dependency of QT duration. It is
worth emphasizing that phenotype-genotype corre-
lations in LQTS patients indicate that LQTS carri-
ers could have QTc as low as 0.42 s, therefore mak-
ing the borderline category broader than previously
expected [4, 18]. Bradycardia may especially lead to
an underestimation of QT duration and simultaneous-
ly bradycardia is known to predispose to TdP.
There is no universal threshold for identifying
significant drug-induced QTc prolongation, and each
drug has to be analyzed on an individual basis. There
is an agreement that a QTc prolongation by > 30 ms
should raise concerns, and with greater concern
when the QTc exceeds > 60 ms, especially if the
QTc prolongs beyond 500 ms [35]. The analysis of
the magnitude of QTc prolongation from baseline
by a drug should be paralleled by evaluating the
absolute value of the prolonged QTc. Again, there
is no universal threshold but reported cases of drug-
induced TdP indicate that almost all of them do oc-
cur in subjects with QTc > 500 ms. These obser-
vations are in agreement with data from congenital
LQTS studies also showing that QTc > 500 ms is
associated with a substantial increase in the risk of
cardiac events [1–4]. The LQTS experience also
indicates that the risk of cardiac events raises ex-
ponentially with QTc prolongation: for every 10ms
increase in QTc there is a 5% increase in the risk
of arrhythmic events [1]. A patient with QTc = 500 ms
will have a 34% higher chance of developing ar-
rhythmia than a subject with QTc = 440 ms
(1.056 = 1.34). Data from published reports on drug-
-induced TdP indicate that the majority of patients
in whom ECG data were available had QTc in the
corrected QT (QTc) interval is computed. Many
methods have been developed to correct the QT
duration for heart rate (Bazett [27], Fridericia [28],
Framingham [29], Hodges et al. [30], Rautaharju
et al. [31], and Karjalainen et al. [32]), but by far the
most commonly used is the formula developed by
Bazett where QTc = QT/(RR½ ). Usually the RR
interval preceding the measured QT is used for this
calculation, but the mean RR intervals from 3–5 con-
secutive beats may be averaged when there is an
apparent sinus (or non-sinus) arrhythmia. Since
most of ECG machines print heart rate for a 10-sec-
ond period of recording, it is very useful to consid-
er printed heart rate and convert it to mean RR in-
terval for a given ECG, instead of using just one or
few preceding beats. Correction formulae aim to
adjust the QT interval to conditions seen during
a heart rate of 60 beats per minute. This calculation
will suffice for most clinical purposes since pa-
tients often have a resting heart rate in the range
of 55–75 beats per minute. However, the Bazett’s
formula becomes less accurate underestimating
repolarization duration at slow heart rates and
overestimating at fast heart rates. Fridericia’s for-
mula performs better than Bazett’s especially at
faster heart rates and it is used most frequently in
the drug approval process. Both Bazett’s and
Fridericia’s formulae are exponential, trying to
reflect the curvilinear QT-RR relationship ob-
served in a wide range of heart rates. However, in
the range of heart rate between 55–85 beats per
minute the pattern of QT-RR relationship is fre-
quently linear. This is why some linear formulae
like the Framingham [29] equation seem to work
quite well. Also, the formula by Rautaharju [31] is
highly recommended especially when used with
proper adjustment for female or male gender.
Another approach to deal with QT duration
while avoiding mathematical heart rate corrections
is to compare absolute QT duration at similar heart
rates (so called RR bin method) [33]. This method
is particularly useful when a long-term holter or
bedside monitoring ECGs are available with suffi-
cient number of beats spanning a wide range of heart
rates.
Table 3. QTc values by age and gender [34].
QTc value [s] Children (1–15 years) Men Women
Normal < 0.44 < 0.43 < 0.45
Borderline 0.44–0.46 0.43–0.45 0.45–0.46
Prolonged > 0.46 > 0.45 > 0.46
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range of 500–600 ms [11, 13], confirming observa-
tions from the congenital LQTS and corresponding
to current regulatory recommendations.
T wave morphology
Observations from ECG analyses in patients
with congenital LQTS demonstrated that specific
genetic forms of LQTS might be associated with
distinctive T wave morphology [36]. LQT1, associ-
ated with a loss of function of the IKs current, is usu-
ally manifested by a broad based T wave. LQT2,
associated with a loss of function in the IKr current,
frequently features low amplitude and notched T
waves. LQT3, associated with a gain of function of
the INa current, is manifested by remote peaked T
waves. These clinical findings were subsequently
confirmed in the experimental setting of drug-in-
duced forms of LQT1 produced by chromanol, LQT2
by D-Sotalol, and LQT3 by ATXII with a differen-
tial ECG recorded from the surface of canine per-
fused wedge preparations [20]. These experiments
also documented the presence and importance of
transmural dispersion of action potential duration
for precipitating reentry ventricular tachyarrhyth-
mias (Fig. 1). Since the peak of the recorded T wave
coincided with the end of repolarization in the
epicardium and the end of the T wave with the end of
repolarization in the M cell zone, measurement of
the Tpeak–Tend duration and its ratio to QT inter-
val was proposed to reflect transmural dispersion,
at least in the experimental setting. As recently dem-
onstrated by Liu et al. [37] this approach identified
extremely effectively in laboratory conditions drugs
prone to induce TdP. Figure 3 shows drug-induced
changes in the Tpeak-Tend/QT ratio for drugs known
to cause QT prolongation and TdP in comparison to
drugs with no such effect. These findings provide the
foundation for applying T wave morphology for iden-
tifying patients prone to developing TdP.
There are conflicting results regarding the pre-
dictive value of Tpeak–Tend in the clinical setting.
The Tpeak–Tend duration recorded from body sur-
face ECG is not yet proven to measure heterogene-
ity of repolarization since the surface ECG is reflect-
ing a multitude of currents in the whole myocardium
not just localized differences in duration of repolari-
zation. Recent studies support Tpeak–Tend interval
as an index of transmural dispersion and vulnerabil-
ity. Yamaguchi et al. [38] observed that that Tpeak–
Tend is more effective than QTc as a predictor of TdP
in patients with acquired LQTS. In patients with
hypertrophic cardiomyopathy, Shimizu et al. [39]
demonstrated that Tpeak–Tend predicts sudden
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Figure 3. Maximal drug-induced change in Tpeak-Tend/QT ratio at concentrations < 100 fold of their free therapeutic
plasma concentration. The black bars represent the compounds that resulted in significant QT prolongation accom-
panied by the development of EAD, R-on-T extrasystoles and TdP; the gray bars represent the compounds that led to
a significant increase in the QT interval but without EAD and EAD-dependent phenomena; and the blank bars
represent the negative compounds. The symbol of * indicates p < 0.05 when compared with the control value of the
compound.
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cardiac death. More studies are needed evaluating
the association between Tpeak–Tend duration and
cardiac events in various patient populations.
T wave morphology is affected by drugs and as
frequently seen the T wave becomes flatter and
broader (Fig. 1), and these visual characteristics
could be quantified by computerized methods in dig-
ital or digitized ECGs [40, 41]. Computerized ECG
parameters reflecting drug-induced changes in re-
polarization include T wave amplitude, slopes of left
and right arms of the T wave, early and late dura-
tion of T wave components as well as notching. In
addition, the analyses of T wave loop morphology
might provide additional information regarding the
presence of baseline or drug-induced alterations that
might predispose to TdP. These novel computer-
ized methods might replace or at least complement
standard QT measurements methods both in a drug
testing setting as well as for clinical cardiac moni-
toring when evaluating safety of administered drugs.
Drug-induced torsades de pointes:
Multiple hit hypothesis
Frequently-prescribed drugs including eryth-
romycin, tamoxifen, or haloperidol affect IKr kinet-
ics, however, they rarely cause QT prolongation and
life-threatening arrhythmias. Susceptibility to drug-
induced QT prolongation and TdP is multifactorial
and a combination of several factors is needed for
arrhythmia to occur (Table 4). Most likely genetic
variations (not obligatory mutations causing LQTS)
in genes encoding the function of ion channels op-
erate as a key factor underlying susceptibility to
drug-induced QT prolongation and TdP [42, 43].
Variations (polymorphisms) in genes encoding ion
channels may cause an increased sensitivity of these
channels to drugs blocking IKr. Recent studies
focused on the associations between genetic polymor-
phisms and QT duration provided proof of the con-
cept of potential importance of genetic predisposi-
tion to QT prolongation in the general population.
The KORA study [44] indicated that NOS1AP pol-
ymorphism could be associated with a 7-milisecond
average increase in QT duration. The Framingham
study [45] identified a 3-milisecond difference as-
sociated with another yet underinvestigated genetic
variation in the KVNH2 gene. It is worth stressing
that terfenadine, which was withdrawn from the
market based on a series of sudden deaths, caused
a 6-milisecond increase in QT duration on average.
Therefore, the range of genetically determined var-
iation in general population is comparable to
a threshold used by the FDA for drug approval.
Polymorphisms in genes encoding enzymes
metabolizing drugs may increase serum levels of
drugs to excessive levels blocking the channel [42].
Borderline prolonged QT duration might be the
phenotypic expression of such polymorphisms and
therefore it is worth paying attention to a baseline
ECG when prescribing drugs that could block IKr or
could interfere with metabolism of drugs blocking
potassium currents. The field of pharmacogenom-
ics is still in its infancy but there is growing evidence
that genetic make-up might be critical for drug-in-
duced QT prolongation.
Women account for 70% of cases of drug-induce
QT prolongation and TdP indicating that sex-related
differences in repolarization duration might predis-
pose women to proarrhythmias [20]. Older age and
pre-existing heart disease (contributing to downre-
gulation of potassium channels) are additional factors
increasing susceptibility to QT prolongation and
proarrhythmia. Bradycardia, whether spontaneous or
drug-induced, also contributes to a proarrhythmic
response due to an increased heterogeneity of repo-
larization during slow heart rates. Electrolyte abnor-
malities including hypokalemia and hypomagnesemia
might also predispose to QT prolongation and TdP.
Concomitant use of several drugs sharing the
same metabolic pathway, such as the major cyto-
chrome P450 (CYP) enzyme systems, is likely to
augment individual drug levels and may increase the
risk of arrhythmias beyond that seen when the
medications are used alone [46]. Drugs including
terfenadine and astemizol were removed from the
market mainly because when prescribed with P450
inhibitors like ketoconazlole or macrolide antibiot-
ics they may result in QT prolongation and fatal ar-
rhythmias. The use of two or more IKr blockers
simultaneously (e.g., erythromycin and pimozide)
Table 4. Factors associated with increased risk of
QT prolongation and torsades de pointes.
Prolonged QTc
Female sex
Advanced age
Bradycardia
Hypokalemia
Hypomagnesemia
Congestive heart failure (low EF)
Cardiac arrhythmias
Combinations of drugs (ion channel blockers,
cytochrome P450 enzymes inhibitors)
Genetic polymorphisms of gene coding cardiac ion
channels or enzymes in liver metabolising drugs
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may also lead to substantial QT prolongation and
subsequent arrhythmias.
The multiple hit hypothesis emphasizes the fact
that rarely one of the above factors is sufficient to
cause drug-induced QT prolongation. Usually,
a combination of several above mentioned factors
must coincide to precipitate drug-induced TdP.
Again, QT prolongation is a precipitating factor
when it is accompanied by transmural dispersion of
repolarization predisposing to reentry arrhythmias.
Unfortunately there are no proven clinical ECG
methods to evaluate the magnitude of such hetero-
geneity. QT dispersion failed to serve as such
a marker. Based on ECGs from perfued wedge pre-
prations, there is emerging evidence that T wave
morphology and Tpeak–Tend duration might pro-
vide clinically useful information regarding hetero-
geneity of repolarization in the myocardium and
propensity to TdP.
Improving safety of administering drugs
The response of a patient to a drug is very in-
dividual and therefore an individualized system of
drug administration and monitoring needs to be
developed, which takes into account baseline QTc
duration and its changes after a drug is introduced.
Pharmacogenomics is a promising field, however,
its clinical application is still a decade or two away.
Therefore, current efforts need to focus on clinical
evaluation and the ECG as a diagnostic and moni-
toring tool available to every physician. Since drug-
induced QT prolongation and TdP are more likely
to occur in prone individuals (Table 5), patients need
to be evaluated regarding baseline probability of
developing drug-induced arrhythmia. Young healthy
patients occasionally taking erythromycin are very
unlikely to develop QT prolongation and TdP. How-
ever, the same erythromycin given to a 70-year old
female with moderate heart failure taking diuretics
(thus with risk of hypokalemia) and taking an an-
tipsychotic drug (with some QT prolonging effect)
might lead to an unfortunate combination of factors
leading to proarrhythmia and sudden death. The first
recommendation is to determine pre-treatment
probability of such incident based on known clini-
cal factors (Table 3). Secondly, a baseline ECG
needs to be recorded to determine whether the pa-
tient does not present with baseline QT prolonga-
tion which could be related to genetic predisposi-
tion, underlying disease process, or drugs current-
ly being taken. QTc should be evaluated based on
manual measurements, not relying on, but also not
neglecting automatic printouts of QTc by ECG ma-
chines. ECGs should be repeated in a period reflect-
ing maximum plasma concentrations of the drug and
the QT should be measured using the same meth-
odology as it was done for baseline ECGs. In case
of significant QTc prolongation by 60 ms or above
500 ms, treatment should be stopped or the combi-
nation of drugs modified to diminish the risk of cardi-
ac events. The proposed model is not routinely exer-
cised with exception for some prespecified conditions
and drugs (for example in atrial fibrillation patients
receiving dofetilide) but would most likely result in
a significant decrease of sudden death cases, otherwise
attributed to underlying diseases and older age. Large
studies are needed to determine the effectiveness of
active ECG monitoring of prone patients taking car-
diac and non-cardiac QT prolonging drugs.
Drug testing
In parallel to individualized safety measures,
regulatory agencies and pharmaceutical companies
are increasingly sensitive to ensure safety of exist-
ing and new compounds entering the market (Ta-
ble 6) [47–50]. Postmarketing studies brought to
attention drug-induced cases of sudden death and
they remain (together with phase III clinical trials)
an important source of information regarding the
safety of a given drug. However, both pharmaceu-
tical companies and regulatory agencies are eager
to determine the potential for QT prolonging or tor-
sadogenic properties of a drug at an early stage of
its development. Starting with the preclinical stage
of investigations, the effects of a drug on IKr currents
in vitro are tested with and without metabolic
Table 5. QT and torsades de pointes safety steps in drug development process.
In vitro screening of the drug and its metabolite for effects on ion channels (IKr) and action potential duration
Screening of the drug and its metabolites for altered repolarization and proarrhythmia in animal studies
Clinical phase I/II studies with protocols incorporating arrhythmia and QT monitoring
Thorough QT studies (if needed)
Clinical studies/trials evaluating risk-benefit ratio of the drug
Postmarketing studies detecting risk of cardiac events
531
Wojciech Zaręba, Drug induced QT prolongation
www.cardiologyjournal.org
inhibitors, and next in laboratory animals where
measuring QT is possible. Phase I and phase II clin-
ical studies are the next important sources of data
regarding the effect of the tested drug on QT dura-
tion, heart rate, and T wave morphology. In the case
of the majority of compounds these tests do not
reveal significant drug-induced repolarization
changes and drugs can proceed to further phases
of development and approval. However, a number
of drugs might have some QT prolonging proper-
ties and depending on the magnitude of effects and
the risk-benefit ratio, the drugs might require stop-
ping the development or further testing in a so
called Thorough QT Study. The Thorough QT
Study consists of careful monitoring of ECG param-
eters during administration of a tested drug (tim-
ing of ECG follows dynamics of plasma concentra-
tion) and during administration of moxifloxacin, an
antibiotic with known QT prolonging effect consid-
ered as positive control (to validate the ability of
the ECG core lab to detect the expected repolari-
zation changes). Drugs with QT prolongation
showing upper confidence intervals below 10 ms
do not raise concerns regarding their QT-related
safety whereas drugs causing QT prolongation
exceeding this threshold might require additional
safety measures during the next phases of devel-
opment, possibly requiring specific warning labe-
ling about the QT prolonging effect, or may not be
recommended for entering the market.
Summary
In conclusion, the cardiac safety of existing and
novel drugs is of growing concern for patients, phy-
sicians, health service systems, as well as drug
manufacturers. Improved understanding of mecha-
nisms through which various medications might
cause abnormalities in repolarization with conse-
quent susceptibility to ventricular arrhythmias helps
develop safer drugs, provides a foundation for more
robust ECG monitoring, and leads to safer utiliza-
tion of new compounds. Novel computerized ap-
proaches for monitoring drug safety aim to provide
more sensitive monitoring tools for early detection
of repolarization changes. There is tremendous
need for broader clinical use of safety precautions
when administering drugs and their combinations
to individual patients. Educating patients and phy-
sicians as well as frequent implementation of ECG
monitoring might decrease beyond expectancies the
risk of sudden death in the general population.
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